文献速递炎症性肠病

102例白细胞介素-10信号缺陷婴儿期起病炎症性肠病患者的临床结局

Clinical outcome of infantile-onset inflammatory bowel disease in 102 patients with interleukin-10 signalling deficiency.
PubMed 文献 · Aliment Pharmacol Ther · 2022-02-20

本研究在单一大三级中心回顾性分析了109例白细胞介素-10信号缺陷患者,其中102例纳入生存分析。73例接受造血干细胞移植,移植后总生存率为64.2%(95%CI 52.8-75.6),未移植者为47.5%(95%CI 14.8-80.2,P=0.47),两组生存概率无显著差异。

要点

  • 109例白细胞介素-10信号缺陷患者中108例为IL10RA突变,1例为IL10RB突变。
  • 73例接受造血干细胞移植,移植后总生存率64.2%(95%CI 52.8-75.6)。
  • 未移植者生存率47.5%(95%CI 14.8-80.2),与移植组比较P=0.47。

核心结论

  • 移植患者与未移植患者的生存概率无显著差异。

研究设计与样本

  • 单一大三级中心回顾性研究,共回顾109例白细胞介素-10信号缺陷患者,其中102例纳入生存分析。
  • 采用Kaplan-Meier法计算生存概率及移植至造口关闭的间隔时间。

主要发现

  • 108例为IL10RA突变,1例为IL10RB突变。
  • 73例接受造血干细胞移植,移植后总生存率为64.2%(95%CI 52.8-75.6)。
  • 未移植者生存率为47.5%(95%CI 14.8-80.2,P=0.47)。
  • 移植至造口关闭的中位时间为19.6个月。
  • 在未接受造血干细胞移植的患者中,合并穿孔(P<0.001)、肠梗阻(P=0.038)及未接受沙利度胺治疗(P<0.001)者的生存概率显著更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infantile-onset inflammatory bowel disease can be caused by defects in interleukin-10 signalling. The natural history and clinical outcomes of allogeneic haematopoietic stem cell transplantation, medical treatment and surgery have not been thoroughly described. AIMS: This study evaluates disease progression and clinical outcome in patients with interleukin-10 signalling deficiency. METHODS: One hundred and nine patients with interleukin-10 signalling deficiency were retrospectively reviewed from a single tertiary centre. The Kaplan-Meier method was applied to calculate probabilities of survival and interval between transplant and stoma closure. RESULTS: One hundred and nine patients were reviewed, and 102 patients were included in the survival analysis. One hundred and eight patients were identified with IL10RA mutations, and one patient harboured IL10RB mutation. Seventy-three patients received haematopoietic stem cell transplantation. The overall survival after transplantation was 64.2% (95% confidence interval, 52.8 to 75.6), and without transplantation, it was 47.5% (95% confidence interval, 14.8 to 80.2, P = 0.47). The median timeframe between transplant and stoma closure was 19.6 months. The probability of survival was significantly lower in patients with perforation (P < 0.001), ileus (P = 0.038) and without thalidomide treatment (P < 0.001) among patients who did not receive haematopoietic stem cell transplantation. The survival probability was not associated with timeframe between transplant and onset, graft source and genotypes. CONCLUSIONS: The survival probability was not significantly different between patients with transplantation and the non-transplanted patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ye Z, Qian L, Hu W, et al. Clinical outcome of infantile-onset inflammatory bowel disease in 102 patients with interleukin-10 signalling deficiency. Aliment Pharmacol Ther. 2022. PMID: 35187668. doi:10.1111/apt.16837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。